Feedback / Questions
olendalizumab (ALXN1007) - Alexion Pharma
Alexion: Q2 FY 2016 Results
(Alexion)
-
Jul 30, 2016 -
"Historical overall response rate 56% at 28 days"; "Historical CR rate 49% at 28 days"
P2 data
•
Graft versus Host Disease
http://files.shareholder.com/downloads/ALXN/1970712006x0x901965/A176F3A4-A533-408E-ACCD-906AD0747FF5/Alexion_2Q_Earnings_Slides_07_28_2016_FINAL.PDF
Jul 30, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious